Sobi sold!Thanks for the ride! My guess is that there is not much more that I can get out of this one.
Swedish Orphan Biovitrum AB
No trades
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
0.0 SEK
3.88 B SEK
26.03 B SEK
179.21 M
About Swedish Orphan Biovitrum AB
Sector
Industry
CEO
Guido Oelkers
Website
Headquarters
Solna
Founded
2001
IPO date
Sep 15, 2006
IPO offer price
13.73 USD
Identifiers
2
ISINSE0000872095
Swedish Orphan Biovitrum AB engages in the research, development, manufacture, and sale of pharmaceuticals. It operates through the Haematology, Immunology, and Specialty Care segments. The Haemotology segment focuses on haemophilia medicines Elocta and Alprolix. The immunology segment offers treatment for serious, disabling, and life-threatening diseases. The Specialty Care segment specializes in the treatment of genetic and metabolic diseases. The company was founded in 2001 and is headquartered in Solna, Sweden.
Related stocks
Swedish Orphan Biovitrum (SOBI.ST) breakout from consolidationSanofi's bid yesterday for SOBI's partner Bioverativ at a 60%+ premium is highly supportive for SOBI's valuation. Strong future in haemophilia products Eloctate and Alprolix. As the European territory (SOBI territory) launches were two years later than the US, SOBI's sales are at an earlier stage, a
See all ideas
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
MEUH
Amundi Core Stoxx Europe 600 -UCITS ETF HEDGED- CapitalisationWeight
0.06%
Market value
9.99 M
USD
STXH
Amundi Index Solutions SICAV - Amundi Core Stoxx Europe 600 UCITS ETF Monthly Hedged to EUR - Dist- DistributionWeight
0.06%
Market value
9.99 M
USD
Explore more ETFs
Frequently Asked Questions
The current price of SOBI is 325.8 SEK — it has decreased by −0.61% in the past 24 hours. Watch Swedish Orphan Biovitrum AB stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on OMXSTO exchange Swedish Orphan Biovitrum AB stocks are traded under the ticker SOBI.
SOBI stock has fallen by −1.76% compared to the previous week, the month change is a −2.93% fall, over the last year Swedish Orphan Biovitrum AB has showed a 4.56% increase.
We've gathered analysts' opinions on Swedish Orphan Biovitrum AB future price: according to them, SOBI price has a max estimate of 441.00 SEK and a min estimate of 290.00 SEK. Watch SOBI chart and read a more detailed Swedish Orphan Biovitrum AB stock forecast: see what analysts think of Swedish Orphan Biovitrum AB and suggest that you do with its stocks.
SOBI reached its all-time high on Oct 28, 2024 with the price of 354.4 SEK, and its all-time low was 10.8 SEK and was reached on Nov 23, 2011. View more price dynamics on SOBI chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
SOBI stock is 1.43% volatile and has beta coefficient of 1.03. Track Swedish Orphan Biovitrum AB stock price on the chart and check out the list of the most volatile stocks — is Swedish Orphan Biovitrum AB there?
Today Swedish Orphan Biovitrum AB has the market capitalization of 112.43 B, it has decreased by −3.88% over the last week.
Yes, you can track Swedish Orphan Biovitrum AB financials in yearly and quarterly reports right on TradingView.
Swedish Orphan Biovitrum AB is going to release the next earnings report on Feb 5, 2026. Keep track of upcoming events with our Earnings Calendar.
SOBI earnings for the last quarter are −8.32 SEK per share, whereas the estimation was 4.65 SEK resulting in a −278.90% surprise. The estimated earnings for the next quarter are 3.88 SEK per share. See more details about Swedish Orphan Biovitrum AB earnings.
Swedish Orphan Biovitrum AB revenue for the last quarter amounts to 7.78 B SEK, despite the estimated figure of 7.73 B SEK. In the next quarter, revenue is expected to reach 8.16 B SEK.
SOBI net income for the last quarter is −2.90 B SEK, while the quarter before that showed 636.00 M SEK of net income which accounts for −555.19% change. Track more Swedish Orphan Biovitrum AB financial stats to get the full picture.
No, SOBI doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 18, 2025, the company has 1.84 K employees. See our rating of the largest employees — is Swedish Orphan Biovitrum AB on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Swedish Orphan Biovitrum AB EBITDA is 17.47 B SEK, and current EBITDA margin is 36.65%. See more stats in Swedish Orphan Biovitrum AB financial statements.
Like other stocks, SOBI shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Swedish Orphan Biovitrum AB stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Swedish Orphan Biovitrum AB technincal analysis shows the sell today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Swedish Orphan Biovitrum AB stock shows the buy signal. See more of Swedish Orphan Biovitrum AB technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.